momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (2888)	8/5/2005 7:51:01 PM
From: Ian@SI	Read Replies (1) of 12215

Is this your kind of company? NexMed (NEXM) : Brean Murray initiates STRONG BUY. Target $4. Firm believes that corporate development will accelerate in 4Q05, bringing NexMed what is likely to be one large pharma co and one mid-level specialty pharma co as partners for NM100060 and Alprox-TD, respectively. Firm believes that Novartis (NVS), which owns the patents for terbinafine and currently sells it as Lamisil, has already tried to lock up NEXM for a six-month exclusive negotiation period during which NVS wanted to evaluate NM100060 thoroughly. Firm believes that NEXM declined the exclusive request because it is also far along in discussions with several other potential large pharma partners.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next